Articles

The industry got a reprieve as pharmaceuticals were exempted from President Trump’s reciprocal tariffs announced this week. However, analysts expect it to be short-lived.

The White House on Wednesday said pharmaceuticals are exempted from the reciprocal tariffs. Jefferies analysts called the impact on biopharma “minimal” at least for now.

Pharma Manufacturing is interested in getting your feedback on the Trump administration’s trade policies and how they could affect your business.

Pharma Manufacturing sat down with Christian Seufert, Lonza’s Head of Advanced Synthesis, which represents about 30% of the CDMO’s revenue.

Faster turnaround times on gene assembly and verification are allowing researchers to focus on their core research activities.

The Swiss-headquartered company has scaled up its operations to become a leading contract development and manufacturing organization focused on profitable growth.

This week, President Donald Trump doubled down on his threat to target the pharma industry with tariffs meant to bring drug manufacturing back to the United States.

Therapeutic enzymes are increasingly important in drug development, but scaling them presents various challenges.

With capabilities supporting its next-generation ADC pipeline scaled up externally, Sutro Biopharma’s operations in San Carlos, California will cease this year.

Understanding the location and existing infrastructure are critical to creating a successful cleanroom.

While the $925 million acquisition of Biovectra was completed in September, Agilent is bringing the Canadian CDMO up to its standards in terms of process and quality.

Major players in the contract development and manufacturing organization industry gathered in New York City this week to provide updates on their infrastructure investments.

The company is investing $1 billion in its Songdo Bio Campus in South Korea, with Plant 1 scheduled for completion this year and full-scale commercial production by 2027.

Best practices for designing automated machinery solutions for bringing these nasal devices to market

By automating and digitizing critical processes, Ori’s platform is designed to streamline manufacturing workflows and overcome bottlenecks that limit patient access.

Eli Lilly, Merck, Pfizer, Purdue University, and The Noramco Group are among the stakeholders looking to help address shortages in the U.S. injectable supply chain.

The Montreal-based company is at risk from potential tariffs from President Donald Trump and Canada’s government that could adversely affect its financial results.

With the right strategies and technologies in place, manufacturers can not only meet the requirements of the proposed legislation but also strengthen their position in an evolving...

Purdue’s Young Institute Pharmaceutical Manufacturing Consortium is working to address bottlenecks in efficiency, contamination control, and regulatory compliance.

Aragen Life Sciences stands to benefit as the biopharma industry looks to derisk its supply chains and shift outsourcing away from China to Indian service providers.

It’s been a topsy-turvy week for President Trump’s tariff proclamations, which have created anxiety and confusion for businesses that rely on trade with Canada and Mexico.

A boundless automation vision with connected data strategies unlocks faster development, streamlines technology transfer, and promotes sustainable growth in life sciences.

President Trump in an address to a joint session of Congress said the European Union and India, among other nations, charge “tremendously higher” tariffs on U.S. goods.

From manufacturing to supply chain strategies, here’s how drug manufacturers are looking at the year ahead.

The company’s experience as a former RNA drug developer gives it a unique edge — it understands not just how to make RNA, but how to make it work in real-world applications.

The Indiana-headquartered pharma giant chose to make its investment announcement this week in Washington, D.C., with newly confirmed Commerce Secretary Howard Lutnick.

With a portfolio that spans first-in-human trials to commercial production, KBI is a solutions provider whose specialty is tackling the toughest molecules.

The first commercial scale “smart” factory is in New Jersey, with other integrated development and manufacturing organization facilities being built in Belgium and Japan.

This year’s outlook for the contract development and manufacturing organization market is cautiously optimistic.

CEO Greg Behar, who took Recipharm’s helm last year, has made targeted investments and divested its non-core sites to become a “more agile” company.